Table 5.
MiRNAs as targets for cancer therapy
| Cancer type | miRNA target and its role in cancer | Delivery system to modulate the miRNA in vivo* | Reference |
|---|---|---|---|
| Breast cancer |
miR-34a – Tumor suppressor |
Cationic liposomes |
[109] |
| Glioblastoma |
miR-145 – Tumor suppressor |
Adenoviruses |
[110] |
| Glioblastoma |
miR-221-222 – Oncogene |
Adenoviruses |
[111] |
| Glioblastoma Multiforme (GBM) |
miR-9 – promote expression of P-gp (a multidrug resistance efflux transporter) |
- Mesenchymal stem cell-derived exosomes |
[112] |
| - To deliver anti-miR-9 to temozolomide-resistant GBM to reduce P-gp expression for resistance reversal | |||
| Hepatocellular carcinoma |
miR-26 – Tumor suppressor |
Adenoviruses |
[113] |
| Lung cancer |
let-7 – Tumor suppressor |
Adenoviruses |
[114] |
| Lung cancer |
miR-34a – Tumor suppressor |
Cationic liposomes |
[115] |
| Lymphoma |
miR-155 – Oncogene |
Polymer-based nanoparticles |
[116] |
| Medulloblastoma |
miR-17 ~ 92 cluster family – Sonic Hedgehog signaling |
8-mer seed-targeting locked nucleic acid (LNA)-modified anti-miR oligonucleotides (nude mice) |
[117] |
| Pancreatic cancer | miR-21 – Oncogene | Lentiviruses | [118] |
* The miRNA target can be modulated by anti-miRNA oligonucleotides or miRNA-expressing constructs (delivered by viral or non-viral vectors).